RFAs: LCRF Research Grants on Overcoming Resistance in Lung Cancer

Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.

Focus Areas

• They encourage applications on a wide variety of topics related to understanding and/or overcoming resistance including but not limited to:
  • Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers. Proposals are encouraged in the areas of histological transformation, oligometastatic disease, oligo-remnant disease, uncommon mutations and non-genomic mechanisms of resistance.
  • Biology and mechanisms of drug resistance to lung cancer therapies including chemotherapy, immunotherapy, radiotherapy, and antibody drug conjugates.
  • Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies.
  • Novel diagnostic approaches (i.e. biomarkers) to monitor treatment response and relapse.
  • Overcoming resistance in difficult to treat sites of metastases such as leptomeningeal and brain metastases.

Funding information

• The maximum award amount is $150,000 for a period of two years (disbursed at $75,000 per year).

Eligibility Criteria

• Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment.
• Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status.
• Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics.
• Ineligible applications and new requests under special circumstances will not be considered after submission deadline.

Ineligibility Criteria

• Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years.
• Applicants are prohibited from applying in more than one of LCRF’s funding tracks in the same cycle.

For more information, visit LCRF.